BPCA/Pediatric Exclusivity Statistics: List of Determinations Including Written Request (updated)
Other New Products
BPCA/Pediatric Exclusivity Statistics: List of Determinations Including Written Request (updated)
Submitted by sharon on Fri, 05/02/2008 - 22:55.Drug to be Discontinued: Tilade Inhaler (nedocromil sodium inhalation aerosol)
Submitted by sharon on Fri, 05/02/2008 - 14:45.Dear Healthcare Professional Letter is available.
Drug Safety Oversight Board Meeting, March 20, 2008 Public Summary
Submitted by sharon on Fri, 05/02/2008 - 13:50.Drug Safety Oversight Board Meeting, March 20, 2008 Public Summary
Prescription Drug User Fee Act (PDUFA) Billable Products
Submitted by sharon on Thu, 05/01/2008 - 19:05.Prescription Drug User Fee Act (PDUFA) Billable Products (updated)
Enbrel (etanercept)
Submitted by sharon on Thu, 05/01/2008 - 18:00.Prescribing information revised to include a BOXED WARNING regarding the risk of infection including tuberculosis.
Guidance for Industry
Submitted by sharon on Thu, 05/01/2008 - 14:10.Comprehensive List of Guidance Documents
Guidance for Industry
Submitted by sharon on Thu, 05/01/2008 - 14:10.New/Revised/Withdrawn List for 2008
Common Technical Document (CTD) Modules/Sections Corresponding to Summary Data Tables in Bioequivalence Submissions to ANDAs (up
Submitted by sharon on Wed, 04/30/2008 - 20:00.Common Technical Document (CTD) Modules/Sections Corresponding to Summary Data Tables in Bioequivalence Submissions to ANDAs (updated)
FDA Approves Amitiza for IBS-C
Submitted by sharon on Tue, 04/29/2008 - 22:45.The U.S. Food and Drug Administration has approved Amitiza (lubiprostone) for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adult women aged 18 and over.
Medical, Statistical, and Clinical Pharmacology Reviews of Pediatric Studies
Submitted by sharon on Tue, 04/29/2008 - 18:35.Medical, Statistical, and Clinical Pharmacology Reviews of Pediatric Studies Conducted under Section 505A and 505B of the FDA (the Act), as amended by the FDA Amendments Act of 2007 (FDAAA)